<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>International Journal of Radiation Research</title>
<title_fa>نشریه پرتو پژوه</title_fa>
<short_title>Int J Radiat Res</short_title>
<subject>Basic Sciences</subject>
<web_url>http://ijrr.com</web_url>
<journal_hbi_system_id>79</journal_hbi_system_id>
<journal_hbi_system_user>journal79</journal_hbi_system_user>
<journal_id_issn>2322-3243</journal_id_issn>
<journal_id_issn_online>2345-4229</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.61882/ijrr</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1396</year>
	<month>7</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2017</year>
	<month>10</month>
	<day>1</day>
</pubdate>
<volume>15</volume>
<number>4</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Study of dosimetric and spatial variations due to applicator positioning during inter-fraction high-dose rate brachytherapy in the treatment of carcinoma of the cervix: A three dimensional dosimetric analysis</title>
	<subject_fa>Radiation Biology</subject_fa>
	<subject>Radiation Biology</subject>
	<content_type_fa>تحقيق بديع</content_type_fa>
	<content_type>Original Research</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;div style=&quot;text-align: justify;&quot;&gt;Background: This study evaluates dosimetric and spatial variations in inter&amp;ndash;fraction applicator positioning in high dose rate (HDR) brachytherapy. Materials and Methods: This study includes 25 retrospective patients of carcinoma of the cervix. Each patient received 5 fractions of HDR intracavitary brachytherapy. High Risk-Clinical Target Volume (HR-CTV) were drawn on CT images. First implant was considered as a reference, and all subsequent CT data sets were rigidly registered on first implant&amp;rsquo;s CT data set. Another point A, called point Aabs, was defined on first plan and all subsequent plans. Registration properties were recorded for all 125 plans that include X, Y, Z DICOM offset, rotational, translational values and normalized D90 (ND90) doses were also recorded. Results: The mean angle of rotation on X, Y and Z axis are 0.63 &amp;plusmn; 1.85 deg, -0.86 &amp;plusmn; 1.30 deg, -1.14 &amp;plusmn; 2.44 deg, respectively. While mean translational motion on X, Y and Z axes are &amp;ndash;2.77 &amp;plusmn; 10.32 mm, -6.12 &amp;plusmn; 9.71 mm and 14.62 &amp;plusmn; 23.83 mm, respectively. Mean ND90, and mean HR-CTV were found to be 1.18 &amp;plusmn; 0.26 and 26.91 &amp;plusmn; 17.70 cc, respectively. Conclusion: Results of the study reveals that translational motion is higher than the rotational motions, and inter &amp;ndash; fraction applicator variation does not produce any significant change in Point A doses. The change in volume coverage is observed only due to applicator motion. HR-CTV coverage decreases with increasing HR-CTV volume. Hence, dose prescription should be based on 3D HR-CTV volume.&lt;br&gt;
&amp;nbsp;&lt;/div&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Brachytherapy, GEC-ESTRO Guidelines</keyword>
	<start_page>377</start_page>
	<end_page>382</end_page>
	<web_url>http://ijrr.com/browse.php?a_code=A-10-1-689&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>M.K. </first_name>
	<middle_name></middle_name>
	<last_name>Goyal</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460015549</code>
	<orcid>7900319475328460015549</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Radiation Oncology, Texas Oncology, Fort Worth, Texas, USA</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>D.V. </first_name>
	<middle_name></middle_name>
	<last_name>Rai</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460015550</code>
	<orcid>7900319475328460015550</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Shobhit University, Meerut, UP, India</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>J. </first_name>
	<middle_name></middle_name>
	<last_name>Manjhi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460015551</code>
	<orcid>7900319475328460015551</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Shobhit University, Meerut, UP, India</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>J.L. </first_name>
	<middle_name></middle_name>
	<last_name>Barker</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460015552</code>
	<orcid>7900319475328460015552</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Radiation Oncology, Texas Oncology, Fort Worth, Texas, USA</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>B.H. </first_name>
	<middle_name></middle_name>
	<last_name>Heintz</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460015553</code>
	<orcid>7900319475328460015553</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Radiation Oncology, Texas Oncology, Fort Worth, Texas, USA</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>K.L. </first_name>
	<middle_name></middle_name>
	<last_name>Shide</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460015554</code>
	<orcid>7900319475328460015554</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Radiation Oncology, Texas Oncology, Fort Worth, Texas, USA</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>T.S. </first_name>
	<middle_name></middle_name>
	<last_name>Kehwar</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>drkehwar@gmail.com</email>
	<code>7900319475328460015555</code>
	<orcid>7900319475328460015555</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Department of Radiation Oncology, Merci Fitzgerald Hospital, Darby, PA 19023, USA</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
